2023 Q3 Form 10-Q Financial Statement

#000149315223028437 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $974.9K $315.9K
YoY Change 314.28% 116.17%
Cost Of Revenue $580.0K $235.7K
YoY Change 431.54% 201.22%
Gross Profit $390.0K $80.19K
YoY Change 209.02% 18.13%
Gross Profit Margin 40.0% 25.38%
Selling, General & Admin $1.257M $2.043M
YoY Change -49.24% -20.18%
% of Gross Profit 322.32% 2547.21%
Research & Development $2.668K $83.85K
YoY Change -98.48% -56.04%
% of Gross Profit 0.68% 104.56%
Depreciation & Amortization $20.50K $19.71K
YoY Change 77.89% 41.31%
% of Gross Profit 5.26% 24.57%
Operating Expenses $1.861M $2.382M
YoY Change -29.81% -13.38%
Operating Profit -$886.3K -$2.066M
YoY Change -64.91% -22.96%
Interest Expense $352.1K $175.2K
YoY Change 19893.47% 171656.86%
% of Operating Profit
Other Income/Expense, Net -$360.3K -$171.7K
YoY Change 1388.39% 44.36%
Pretax Income -$1.247M -$2.238M
YoY Change -51.11% -20.11%
Income Tax $1.886K $2.865K
% Of Pretax Income
Net Earnings -$1.248M -$2.241M
YoY Change -51.03% -20.03%
Net Earnings / Revenue -128.06% -709.24%
Basic Earnings Per Share -$0.70 -$3.06
Diluted Earnings Per Share -$0.70 -$3.06
COMMON SHARES
Basic Shares Outstanding 2.450M shares 13.97M shares
Diluted Shares Outstanding 1.777M shares 732.3K shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.060M $112.5K
YoY Change 271.02% -94.27%
Cash & Equivalents $1.056M $112.5K
Short-Term Investments
Other Short-Term Assets $370.0K $374.7K
YoY Change 21.25% 51.29%
Inventory $254.2K $280.0K
Prepaid Expenses
Receivables $116.8K $74.91K
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.792M $842.1K
YoY Change 90.15% -66.95%
LONG-TERM ASSETS
Property, Plant & Equipment $772.4K $659.4K
YoY Change 69.27% 39.4%
Goodwill $8.225M
YoY Change
Intangibles $1.750M
YoY Change 1218.97%
Long-Term Investments $1.080M $1.132M
YoY Change -15.71% -15.98%
Other Assets
YoY Change
Total Long-Term Assets $17.68M $5.797M
YoY Change 373.35% 49.53%
TOTAL ASSETS
Total Short-Term Assets $1.792M $842.1K
Total Long-Term Assets $17.68M $5.797M
Total Assets $19.48M $6.639M
YoY Change 316.31% 3.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.850M $1.845M
YoY Change 168.29% 295.01%
Accrued Expenses $980.0K $1.429M
YoY Change 12.28% 94.34%
Deferred Revenue
YoY Change
Short-Term Debt $880.0K $770.0K
YoY Change
Long-Term Debt Due $820.0K $263.9K
YoY Change
Total Short-Term Liabilities $4.884M $4.469M
YoY Change 194.05% 249.18%
LONG-TERM LIABILITIES
Long-Term Debt $1.100M $0.00
YoY Change
Other Long-Term Liabilities $13.12M $3.873M
YoY Change 658.86% 116.7%
Total Long-Term Liabilities $14.22M $3.873M
YoY Change 722.48% 116.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.884M $4.469M
Total Long-Term Liabilities $14.22M $3.873M
Total Liabilities $19.10M $8.344M
YoY Change 463.35% 171.94%
SHAREHOLDERS EQUITY
Retained Earnings -$55.80M -$54.60M
YoY Change 18.72% 22.7%
Common Stock $56.20M $52.87M
YoY Change 16.34% 4358467.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $372.8K -$1.705M
YoY Change
Total Liabilities & Shareholders Equity $19.48M $6.639M
YoY Change 316.31% 3.33%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$1.248M -$2.241M
YoY Change -51.03% -20.03%
Depreciation, Depletion And Amortization $20.50K $19.71K
YoY Change 77.89% 41.31%
Cash From Operating Activities -$1.250M -$1.644M
YoY Change -24.16% -12.2%
INVESTING ACTIVITIES
Capital Expenditures $110.0K $261.5K
YoY Change -3766.67% -8024.55%
Acquisitions
YoY Change
Other Investing Activities -$2.150M $0.00
YoY Change -100.0%
Cash From Investing Activities -$2.260M -$261.5K
YoY Change 74983.06% 5236.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.440M -169.9K
YoY Change -17719.05%
NET CHANGE
Cash From Operating Activities -1.250M -1.644M
Cash From Investing Activities -2.260M -261.5K
Cash From Financing Activities 4.440M -169.9K
Net Change In Cash 930.0K -2.076M
YoY Change -155.47% 10.55%
FREE CASH FLOW
Cash From Operating Activities -$1.250M -$1.644M
Capital Expenditures $110.0K $261.5K
Free Cash Flow -$1.360M -$1.906M
YoY Change -17.34% 1.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001417926
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
usd
us-gaap Investment Income Net
InvestmentIncomeNet
usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
INVO Proceeds From Option Exercises
ProceedsFromOptionExercises
usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
INVO Fair Value Of Warrants Issued With Debt
FairValueOfWarrantsIssuedWithDebt
usd
INVO Initial Rou Asset And Lease Liability
InitialRouAssetAndLeaseLiability
usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
INVO Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
usd
CY2022Q4 INVO Share Based Compensation Arrangement By Share Based Payment Award Non Options Aggregate Intrinsic Value Warrants Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsAggregateIntrinsicValueWarrantsOutstanding
usd
INVO Share Based Compensation Arrangement By Share Based Payment Award Non Options Aggregate Intrinsic Value Warrants Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsAggregateIntrinsicValueWarrantsGranted
usd
INVO Share Based Compensation Arrangement By Share Based Payment Award Non Options Aggregate Intrinsic Value Warrants Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsAggregateIntrinsicValueWarrantsExercised
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
shares
INVO Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
INVO Share Based Compensation Arrangement By Share Based Payment Award Non Options Aggregate Intrinsic Value Warrants Forfeiture
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsAggregateIntrinsicValueWarrantsForfeiture
usd
CY2023Q2 INVO Share Based Compensation Arrangement By Share Based Payment Award Non Options Aggregate Intrinsic Value Warrants Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsAggregateIntrinsicValueWarrantsOutstanding
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39701
dei Entity Registrant Name
EntityRegistrantName
INVO Bioscience, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4036208
dei Entity Address Address Line1
EntityAddressAddressLine1
5582 Broadcast Court
dei Entity Address City Or Town
EntityAddressCityOrTown
Sarasota
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34240
dei City Area Code
CityAreaCode
(978)
dei Local Phone Number
LocalPhoneNumber
878-9505
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
INVO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2449662 shares
CY2023Q2 us-gaap Cash
Cash
112485 usd
CY2022Q4 us-gaap Cash
Cash
90135 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
74908 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
77149 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
280018 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
263602 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
374714 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
190201 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
842125 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
621087 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
659442 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
436729 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4004962 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1808034 usd
CY2023Q2 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
1132365 usd
CY2022Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
1237865 usd
CY2023Q2 us-gaap Assets
Assets
6638894 usd
CY2022Q4 us-gaap Assets
Assets
4103715 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1844629 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1349038 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1202420 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
946262 usd
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
161187 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
119876 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
227026 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
231604 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4469150 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3409424 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3873289 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1669954 usd
CY2023Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1949 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1949 usd
CY2023Q2 us-gaap Liabilities
Liabilities
8344388 usd
CY2022Q4 us-gaap Liabilities
Liabilities
5081327 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
6250000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
6250000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
826886 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
826886 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
608611 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
608611 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
83 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
61 usd
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
52869346 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
48805860 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54574923 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-49783533 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1705494 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-977612 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6638894 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4103715 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
315902 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
146135 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
663927 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
308733 usd
CY2023Q2 INVO Costs Of Revenue
CostsOfRevenue
235714 usd
CY2022Q2 INVO Costs Of Revenue
CostsOfRevenue
170526 usd
INVO Costs Of Revenue
CostsOfRevenue
466719 usd
INVO Costs Of Revenue
CostsOfRevenue
367207 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2042609 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2444586 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4373443 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4991714 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
83850 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
190761 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
157370 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
294941 usd
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
19705 usd
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
22083 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
38792 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
37630 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
2381879 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
2827956 usd
us-gaap Operating Expenses
OperatingExpenses
5036324 usd
us-gaap Operating Expenses
OperatingExpenses
5691492 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2065977 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2681821 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4372397 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5382759 usd
CY2023Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3788 usd
CY2022Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-117978 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-23947 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-189095 usd
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
48 usd
us-gaap Investment Income Net
InvestmentIncomeNet
273 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
175192 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
102 usd
us-gaap Interest Expense
InterestExpense
391781 usd
us-gaap Interest Expense
InterestExpense
1558 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-265 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-888 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-400 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1914 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-171669 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-118920 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-416128 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-192294 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2237646 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2800741 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4788525 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5575053 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2865 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2865 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2240511 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2801541 usd
us-gaap Net Income Loss
NetIncomeLoss
-4791390 usd
us-gaap Net Income Loss
NetIncomeLoss
-5575853 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.06
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.23
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.06
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.23
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
732255 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
605760 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
677684 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
604123 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
732255 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
605760 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
677684 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
604123 shares
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7310680 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
328548 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
116766 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
315000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
861284 usd
us-gaap Net Income Loss
NetIncomeLoss
-5575853 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3356425 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-977612 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-977612 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
51565 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
244176 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2728938 usd
INVO Stock Issued During Period Value New Issues With Notes Payable
StockIssuedDuringPeriodValueNewIssuesWithNotesPayable
56314 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2375 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
652750 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
327390 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.23
us-gaap Net Income Loss
NetIncomeLoss
-4791390 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1705494 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1705494 usd
us-gaap Profit Loss
ProfitLoss
-4791390 usd
us-gaap Profit Loss
ProfitLoss
-5575853 usd
INVO Noncash Stock Compensation Issued For Services
NoncashStockCompensationIssuedForServices
244176 usd
INVO Noncash Stock Compensation Issued For Services
NoncashStockCompensationIssuedForServices
116766 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
51565 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
328548 usd
us-gaap Share Based Compensation
ShareBasedCompensation
652750 usd
us-gaap Share Based Compensation
ShareBasedCompensation
861284 usd
INVO Noncash Compensation For Services
NoncashCompensationForServices
90000 usd
INVO Noncash Compensation For Services
NoncashCompensationForServices
30000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
301098 usd
INVO Loss From Equity Method Investments
LossFromEquityMethodInvestments
23947 usd
INVO Loss From Equity Method Investments
LossFromEquityMethodInvestments
189095 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
38792 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
37629 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2241 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6015 usd
us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
16416 usd
us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
-5777 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
184513 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-35069 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
432654 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
23553 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
256158 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-72885 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
41311 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
71457 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
1829 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
4655 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
62938 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2792860 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3950920 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
261505 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8338 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1517 usd
INVO Investment In Joint Ventures
InvestmentInJointVentures
8447 usd
INVO Investment In Joint Ventures
InvestmentInJointVentures
76937 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-269952 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-86792 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
714000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2728938 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
315000 usd
INVO Proceeds From Option Exercises
ProceedsFromOptionExercises
2375 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
360151 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3085162 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
315000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
22350 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3722712 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
90135 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5684871 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
112485 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1962159 usd
us-gaap Interest Paid Net
InterestPaidNet
5720 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2847 usd
INVO Fair Value Of Warrants Issued With Debt
FairValueOfWarrantsIssuedWithDebt
327390 usd
INVO Initial Rou Asset And Lease Liability
InitialRouAssetAndLeaseLiability
2312892 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84B_eus-gaap--UseOfEstimates_zf6QDr1PJmna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_z3ZkAJgJygpj">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.06
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.06
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.62
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.07
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_z483iLU1Vrg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zI6ocnaku4bf">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Corporation (“FDIC”) limits. As of June 30, 2023, the Company did not have cash balances in excess of FDIC limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.23
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.06
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.07
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2240511 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2801541 usd
us-gaap Net Income Loss
NetIncomeLoss
-4791390 usd
us-gaap Net Income Loss
NetIncomeLoss
-5575853 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
732255 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
732255 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
605760 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
605760 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
677684 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
677684 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
604123 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
604123 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
732255 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
732255 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
605760 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
677684 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
604123 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
524526 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
87488 shares
us-gaap Net Income Loss
NetIncomeLoss
-4800000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5600000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54600000 usd
INVO Net Income Loss Related To Non Cash Expenses
NetIncomeLossRelatedToNonCashExpenses
1400000 usd
INVO Net Income Loss Related To Non Cash Expenses
NetIncomeLossRelatedToNonCashExpenses
1600000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2700000 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
700000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
300000 usd
CY2021Q2 us-gaap Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
1.50 pure
INVO Investment In Unconsolidated Variable Interest Entities
InvestmentInUnconsolidatedVariableInterestEntities
1132365 usd
CY2022 INVO Investment In Unconsolidated Variable Interest Entities
InvestmentInUnconsolidatedVariableInterestEntities
1237865 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
68723 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
217273 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
194879 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
280018 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
263602 usd
CY2023Q2 INVO Earning From Unconsolidated Variable Interest Entities
EarningFromUnconsolidatedVariableInterestEntities
3788 usd
CY2022Q2 INVO Earning From Unconsolidated Variable Interest Entities
EarningFromUnconsolidatedVariableInterestEntities
-117978 usd
INVO Earning From Unconsolidated Variable Interest Entities
EarningFromUnconsolidatedVariableInterestEntities
-23947 usd
INVO Earning From Unconsolidated Variable Interest Entities
EarningFromUnconsolidatedVariableInterestEntities
-189095 usd
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
62745 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
192059 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
153267 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
659442 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
436729 usd
CY2023Q2 us-gaap Depreciation
Depreciation
19705 usd
CY2022Q2 us-gaap Depreciation
Depreciation
21630 usd
us-gaap Depreciation
Depreciation
38792 usd
us-gaap Depreciation
Depreciation
36725 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
452 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
904 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4004962 usd
CY2023Q2 INVO Right Of Use Assets
RightOfUseAssets
4004962 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.132 pure
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
227026 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3873289 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4100315 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
156465 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
392869 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
392688 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
401581 usd
CY2023Q2 INVO Lessee Operating Lease Liability Payments Due After Year Three
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
4197510 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5541113 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1440798 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4100315 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
285961 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
107356 usd
CY2023Q2 INVO Financing Fee Related Party Demand Notes Percentage
FinancingFeeRelatedPartyDemandNotesPercentage
0.10 pure
CY2023Q2 INVO Annual Interest Related Party Demand Notes Percentage
AnnualInterestRelatedPartyDemandNotesPercentage
0.10 pure
CY2023Q2 INVO Annual Interest Related Party Demand Notes Percentage
AnnualInterestRelatedPartyDemandNotesPercentage
0.10 pure
CY2023Q2 INVO Interest Related Party Demand Debentures Percentage
InterestRelatedPartyDemandDebenturesPercentage
0.08 pure
CY2023Q2 INVO Interest Related Party Demand Conversion Price
InterestRelatedPartyDemandConversionPrice
10.40
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
285961 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
107356 usd
CY2023Q2 us-gaap Notes Payable
NotesPayable
1033888 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
762644 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
17500 shares
CY2022Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
200000 usd
CY2022Q4 us-gaap Debt Instrument Description
DebtInstrumentDescription
These notes accrue 10% annual interest accrues from the date of issuance. These notes are callable with 10 days prior written notice. At maturity, the Company agreed to pay outstanding principal, a 10% financing fee and accrued interest
CY2023Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
410000 usd
CY2023Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
410000 usd
CY2022Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
310000 usd
CY2023Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
12.00
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
19375 shares
CY2023Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.10 pure
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2023-12-31
CY2023Q1 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.08 pure
CY2023Q1 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.08 pure
CY2023Q1 us-gaap Share Price
SharePrice
10.40
CY2023Q1 us-gaap Share Price
SharePrice
10.40
CY2023Q1 INVO Percentage Of Debentures Outstanding
PercentageOfDebenturesOutstanding
0.50 pure
CY2023Q1 INVO Percentage Of Debentures Outstanding
PercentageOfDebenturesOutstanding
0.50 pure
CY2023Q1 us-gaap Sale Of Stock Description Of Transaction
SaleOfStockDescriptionOfTransaction
(i) in a minimum amount of not less than $25,000 and (ii) in a maximum amount of up to the lesser of (a) $750,000 or (b) 200% of the Company’s average daily trading value of the Common Stock
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2375 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
64850 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
68.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
59048 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.74
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
297 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2346 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
72.38
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
121255 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.10
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
71251 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
62.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.036 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0369 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.019 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.066 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.149 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.104 pure
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1616401 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
654925 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
25864 shares
CY2022Q4 INVO Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price Warrants
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceWarrants
30.20
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
432618 shares
INVO Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice
12.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
115000 shares
INVO Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Of Warrants Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrantsExercised
0.20
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
378849 shares
CY2023Q2 INVO Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price Warrants
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceWarrants
20.41
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2865 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2865 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800 usd
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0 pure
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0 pure

Files In Submission

Name View Source Status
invo-20230630_lab.xml Edgar Link unprocessable
invo-20230630_cal.xml Edgar Link unprocessable
0001493152-23-028437-index-headers.html Edgar Link pending
0001493152-23-028437-index.html Edgar Link pending
0001493152-23-028437.txt Edgar Link pending
0001493152-23-028437-xbrl.zip Edgar Link pending
ex10-1.htm Edgar Link pending
ex10-2.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
invo-20230630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
invo-20230630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
invo-20230630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending